Lactiga Announces NIH-Funded Partnership with Mount Sinai

Oct 14, 2020 | Awards & Announcements

Lactiga announced today a collaboration agreement with the Icahn School of Medicine at Mount Sinai to advance preclinical research into LCTG-001 as a potential treatment for COVID-19 patients. The collaborative partners secured an NIH R01 Emergency Award of over $2MM to advance this study.

In the News

November 9, 2021

Got milk COVID-19 antibodies?

https://www.thestar.com/business/mars/2021/06/09/got-milk-covid-19-antibodies.html?rf

In the News

November 9, 2021

Can antibodies from human breast milk help in the COVID-19 fight?

https://www.theglobeandmail.com/canada/article-can-antibodies-from-human-breast-milk-help-in-the-covid-19-fight/

Press Releases

November 1, 2021

Lactiga Announces NIH-Funded Partnership with Mount Sinai to Advance its Patented Biologic for COVID-19 Treatment

Original Post PRINCETON, N.J.--(BUSINESS WIRE)--Lactiga Inc., a biotechnology company advancing its patented anti-infective biologic, LCTG-001, announced today a collaboration agreement ...

2023